Search

Rick Kendall

Based in California, Dr Rick Kendall is vice president of research at Kite Pharma and is responsible for the company’s research pipeline and developing CAR-T technology. Dr Kendall was executive director of Oncology Research at Amgen, where he directed a group of 90+ scientists, and was responsible for the development of the Amgen cancer franchise strategy aligning research with other functions including Chemistry, Protein Sciences, Medical Translational Sciences, Development and Commercial. Results included 17 clinical candidate molecules made up of 9 small molecules and 8 protein therapeutics. Dr Kendall holds an associate adjunct professor position in the Department of Molecular, Cellular and Developmental Biology, at the University of California at Santa Barbara. Prior to joining the board of Phylogica in April 2017, Dr Kendall has consulted on the development of the company’s assets including the iMyc oncology program and Functional Penetrating Phylomer (FPP) intracellular drug delivery technology.
Bio last updated 20 Oct 2018

Positions - Previous

PositionCompanyYearCompany's current rankWA staff
Non-Executive Director
Phylogica
Phylogica
2017 - 2017213

Total Shareholder Return as at 28/09/18

1 year TSR5 year TSR
35thSportsHero180%-39%
65thAusCann Group Holdings116%61%
567thPhylogica-23%17%
664thPLC Financial Solutions-39%-41%
739 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Revenue

211th↓AusCann Group Holdings$54k
212th↓Activistic$49k
213th↓Phylogica$48k
214th↓SportsHero$23k
215th-PLC Financial Solutions$20k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer